Mehdi Boostani

Dr. Mehdi Boostani

Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in International Journal of Dermatology
Verified
Journal Article
Open access
MBMehdi Boostani
Mehdi Boostani
ABAndrás Bánvölgyi
András Bánvölgyi
Mohamad GoldustMohamad Goldust
Mohamad Goldust
Carmen CantisaniCarmen Cantisani
Carmen Cantisani
PPPaweł Pietkiewicz
Paweł Pietkiewicz
Norbert KissNorbert Kiss
Norbert Kiss

2 October 2024 in International Journal of Dermatology
Verified
Journal Article
Open access
MBMehdi Boostani
Mehdi Boostani
SBSzabolcs Bozsányi
Szabolcs Bozsányi
MSMariano Suppa
Mariano Suppa
Carmen CantisaniCarmen Cantisani
Carmen Cantisani
KLKende Lőrincz
Kende Lőrincz
Norbert KissNorbert Kiss
Norbert Kiss
Mohs micrographic surgery (MMS) is the gold standard for removing basal cell carcinomas (BCCs) due to its ability to guarantee 100% margin evaluation through frozen section histopathology, offering the highest cure rate among current treatments. However, noninvasive imaging technologies have emerged as promising alternatives to clinical assessment for defining presurgical margins. This systematic scoping review examines the efficacy of these imaging modalities, focusing on those approved for clinical use by the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA). A systematic search of EMBASE, Scopus, PubMed, and the Cochrane Public Library databases identified 11 relevant studies out of 2123 records, encompassing 644 lesions across five imaging techniques. The findings suggest that dermoscopy, high‐frequency ultrasound (HFUS), optical coherence tomography (OCT), line‐field optical coherence tomography (LC‐OCT), and reflectance confocal microscopy (RCM) show potential in detecting BCC margins, which could enhance MMS by providing better preoperative planning, informing patients of expected defect size, aiding in reconstruction decisions, and reducing overall procedure costs. This review discusses the benefits and limitations of each technique, offering insights into how these innovations could influence the future of BCC management. Emerging imaging techniques could enhance MMS by improving BCC margin assessment and reducing costs. Their adoption will depend on price and ease of use.

16 July 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
MBMehdi Boostani
Mehdi Boostani
ABAndrás Bánvölgyi
András Bánvölgyi
Christos C. ZouboulisChristos C. Zouboulis
Christos C. Zouboulis
NGNoah Goldfarb
Noah Goldfarb
MSMariano Suppa
Mariano Suppa
NKNorbert Kiss
Norbert Kiss

10 June 2025 in JAAD International
Verified
Journal Article
Open access
MBMehdi Boostani
Mehdi Boostani
GPGiovanni Pellacani
Giovanni Pellacani
XWXimena Wortsman
Ximena Wortsman
MSMariano Suppa
Mariano Suppa
MGMohamad Goldust
Mohamad Goldust
Norbert KissNorbert Kiss
Norbert Kiss
Basal cell carcinoma (BCC), the most common skin cancer, requires accurate subtyping for optimal treatment. While histopathology is the gold standard, noninvasive imaging offers a biopsy-free alternative, though its accuracy remains unclear. To assess the diagnostic accuracy of Food and Drug Administration- and European Medicines Agency-approved noninvasive imaging techniques for BCC subtyping. A systematic review included 19 studies (2650 lesions) from EMBASE, Scopus, PubMed, and Cochrane Library (published up to November 30, 2024). Evaluated modalities included dermoscopy, high-frequency ultrasound (HFUS), dermoscopy-guided HFUS (DG-HFUS), optical coherence tomography (OCT), high-definition OCT (HD-OCT), dynamic OCT (D-OCT), line-field confocal OCT (LC-OCT), and reflectance confocal microscopy. Dermoscopy showed moderate accuracy (81.9% sensitivity, 81.8% specificity for superficial BCC [sBCC]). DG-HFUS outperformed HFUS (82.4% sensitivity, 91.3% specificity). LC-OCT had the highest accuracy, achieving 100% sensitivity for infiltrative BCC. D-OCT distinguished subtypes at 150 μm depth; branching vessels at 300 μm increased nBCC risk (relative risk = 1.53, P = .016). HD-OCT had 100% sensitivity for sBCC but lower accuracy for other subtypes. Reflectance confocal microscopy had 88.9% sensitivity for non-sBCC but only 33.3% for aggressive subtypes. Study heterogeneity and inconsistent protocols limit comparability. LC-OCT and HD-OCT offer the highest accuracy, while DG-HFUS outperforms dermoscopy and HFUS, making them strong noninvasive alternatives.

3 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SBSzabolcs Bozsányi
Szabolcs Bozsányi
MBMehdi Boostani
Mehdi Boostani
KFKlára Farkas
Klára Farkas
PHPhyllida Hamilton-Meikle
Phyllida Hamilton-Meikle
NVNoémi Nóra Varga
Noémi Nóra Varga
Norbert KissNorbert Kiss
Norbert Kiss
Background: Basal cell carcinoma (BCC) is the most common type of skin cancer in the Caucasian population. Currently, invasive biopsy is the only way of establishing the histological subtype (HST) that determines the treatment options. Our study aimed to evaluate whether optically guided high-frequency ultrasound (OG-HFUS) imaging could differentiate aggressive HST BCCs from low-risk tumors. Methods: We conducted prospective clinical and dermoscopic examinations of BCCs, followed by 33 MHz OG-HFUS imaging, surgical excision, and a histological analysis. We enrolled 75 patients with 78 BCCs. In total, 63 BCCs were utilized to establish a novel OG-HFUS risk classification algorithm, while 15 were employed for the validation of this algorithm. The mean age of the patients was 72.9 ± 11.2 years. Histology identified 16 lesions as aggressive HST (infiltrative or micronodular subtypes) and 47 as low-risk HST (superficial or nodular subtypes). To assess the data, we used a one-sided Fisher’s exact test for a categorical analysis and a Receiver Operating Characteristic (ROC) curve analysis to evaluate the diagnostic accuracy. Results: OG-HFUS distinguished aggressive BCC HSTs by their irregular shape (p < 0.0001), ill-defined margins (p < 0.0001), and non-homogeneous internal echoes (p = 0.004). We developed a risk-categorizing algorithm that differentiated aggressive HSTs from low-risk HSTs with a higher sensitivity (82.4%) and specificity (91.3%) than a combined macroscopic and dermoscopic evaluation (sensitivity: 40.1% and specificity: 73.1%). The positive and negative predictive values (PPV and NPV, respectively) for dermoscopy were 30.2% and 76.8%, respectively. In comparison, the OG-HFUS-based algorithm demonstrated a PPV of 94.7% and an NPV of 78.6%. We verified the algorithm using an independent image set, n = 15, including 12 low-risk and 3 high-risk (high-risk) with two blinded evaluators, where we found a sensitivity of 83.33% and specificity of 91.66%. Conclusions: Our study shows that OG-HFUS can identify aggressive BCC HSTs based on easily identifiable morphological parameters, supporting early therapeutic decision making.

28 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
NVNoémi Nóra Varga
Noémi Nóra Varga
MBMehdi Boostani
Mehdi Boostani
KFKlára Farkas
Klára Farkas
BABanvolgyi Andras
Banvolgyi Andras
KLKende Lőrincz
Kende Lőrincz
Norbert KissNorbert Kiss
Norbert Kiss
Melanoma is the most aggressive form of skin cancer that is known for its metastatic potential and has an increasing incidence worldwide. Breslow thickness, which determines the staging and surgical margin of the tumor, is unavailable at initial diagnosis. Novel imaging techniques for assessing Breslow thickness lack comparative data. This study evaluates optically guided high-frequency ultrasound (OG-HFUS) and multispectral imaging (MSI) for preoperative estimation of Breslow thickness and staging. We enrolled 101 patients with histologically confirmed primary melanoma and categorized them based on tumor thickness. Optically guided 33 MHz HFUS and MSI were utilized for the assessment. Our MSI-based algorithm categorized melanomas into three subgroups with a sensitivity of 62.6%, specificity of 81.3%, and fair agreement (κ = 0.440, CI: 0.298–0.583). In contrast, OG-HFUS demonstrated a sensitivity of 91.8%, specificity of 96.0%, and almost perfect agreement (κ = 0.858, CI: 0.763–0.952). OG-HFUS performed better than MSI in estimating Breslow thickness, emphasizing its potential as a valuable tool for melanoma diagnosis and patient management. OG-HFUS holds promise for enhancing preoperative staging and treatment decision-making in melanoma.